These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 28918104)

  • 21. Prognostic value of absolute lymphocyte/monocyte ratio, red cell distribution width and neutrophil/ lymphocyte ratio in diffuse large B-cell lymphoma patients.
    Hasan KM; Elmeshhedany AY
    Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):61-68. PubMed ID: 34933732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
    Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
    Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
    Procházka V; Pytlík R; Janíková A; Belada D; Sálek D; Papajík T; Campr V; Fürst T; Furstova J; Trněný M
    PLoS One; 2014; 9(7):e102594. PubMed ID: 25058337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
    Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
    Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
    Keam B; Ha H; Kim TM; Jeon YK; Lee SH; Kim DW; Kim CW; Heo DS
    Leuk Lymphoma; 2015 Jul; 56(7):2032-8. PubMed ID: 25382617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
    Batty N; Ghonimi E; Feng L; Fayad L; Younes A; Rodriguez MA; Romaguera JE; McLaughlin P; Samaniego F; Kwak LW; Hagemeister FB
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):15-8. PubMed ID: 23137719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
    Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ; Shin DH
    Ann Oncol; 2010 Jan; 21(1):140-4. PubMed ID: 19887468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
    Li YL; Gu KS; Pan YY; Jiao Y; Zhai ZM
    BMC Cancer; 2014 May; 14():341. PubMed ID: 24884604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
    Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Papotti R; Ferrari A; Baldini L; Gobbi P; Levy I; Pugliese G; Federico M; Polliack A; Pozzi S; Sacchi S
    Hematol Oncol; 2020 Oct; 38(4):439-445. PubMed ID: 32495944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients?
    Koh YW; Park CS; Yoon DH; Suh C; Huh J
    Eur J Haematol; 2014 Oct; 93(4):340-8. PubMed ID: 24766257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen].
    Zhang J; Gu Y; Wu X; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1912-1918. PubMed ID: 33283719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
    Lisenko K; Dingeldein G; Cremer M; Kriegsmann M; Ho AD; Rieger M; Witzens-Harig M
    BMC Cancer; 2017 May; 17(1):359. PubMed ID: 28532396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
    Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
    Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
    Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.
    Li YL; Shi ZH; Wang X; Gu KS; Zhai ZM
    BMC Cancer; 2019 Nov; 19(1):1049. PubMed ID: 31694577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.
    Matsuki E; Bohn OL; El Jamal S; Pichardo JD; Zelenetz AD; Younes A; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):572-580. PubMed ID: 30106758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
    Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.